SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing renewed market attention driven by its institutional-grade post-quantum security features and its classification as a digital commodity. While the community remains divided between long-term holders optimistic about its real-world asset tokenization potential and bears focused on historic price performance, active discussions highlight a surge in trading volume and increased social dominance.

U.S. Gold Corp. engages in the exploration of gold properties. It has properties in CK Gold Project, Wyoming, Challis Gold Project, Idaho, and Keystone, Nevada. The company was founded in 1967 and is headquartered in Elko, NV.

U.S. Gold Corp

U.S. Gold Corp ($USAU) is trending as investors focus on its near-term catalysts, including its upcoming inclusion in the Russell index and the highly anticipated completion of a feasibility study for the CK Gold Project. While community members highlight the project's de-risking and potential for institutional inflows, discussions are also dominated by concerns over the high volume of automated accounts pumping the stock.

Norfolk Southern Corp. is a transportation company, which engages in the rail transportation of raw materials, intermediate products, and finished goods. The company also transports overseas freight through several Atlantic and Gulf Coast ports. Its services include property leases and sales, wire line or pipeline and fiber optics projects, access property, managing private crossings, promoting businesses with signboards, and natural resource management. The company was founded on July 23, 1980, and is headquartered in Atlanta, GA.

Norfolk Southern Corp.

Norfolk Southern is trending as investors react to a significant accounting shift involving a multi-million dollar lease renewal in Atlanta, which the company has reclassified as a finance lease. Community discourse is currently split between analyzing the impact of this increased balance sheet leverage on the company's long-term financial health and ongoing discussions regarding operational challenges and broader rail sector sentiment.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is seeing significant community engagement as investors debate its long-term potential following recent integrations and post-quantum security developments. While some participants express frustration over price volatility and token supply concerns, others are actively accumulating the asset, citing the project's institutional partnerships and foundational role in the evolving AI agent sector.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is seeing heightened investor attention following a series of clinical wins and regulatory milestones in its oncology and immunology portfolios, including strong performance data for its multiple myeloma franchise. While the community remains focused on these pipeline developments and growth catalysts, discussion is balanced by ongoing monitoring of significant talc-related legal liabilities and potential regulatory impacts on pricing.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render is experiencing a surge in community interest and market activity as investors highlight its pivotal role in the decentralized AI compute and DePIN sectors. The sentiment is heavily bolstered by ongoing discussions regarding its real-world utility, integration with industry giants, and anticipation for future network growth.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor attention as community members debate its potential to decouple from Bitcoin and outperform as a peer-to-peer electronic cash system. Discussions are heavily focused on its resilience, upcoming protocol upgrades, and potential for a breakout as participants speculate on it reclaiming its position as a market leader.

Agree Realty Corp. is a real estate investment trust, which engages in the ownership, acquisition, development, and management of retail properties net leased to industry tenants. It focuses on the long-term, fee simple ownership of properties net leased to national and large regional retailers. The company was founded by Richard Agree in 1971 and is headquartered in Royal Oak, MI.

Agree Realty Corp.

Agree Realty (ADC) is trending as investors monitor its resilient performance in the net-lease REIT sector, with the community frequently debating its growth trajectory and dividend quality relative to peers like Realty Income. Discussions are anchored in the firm's strategic management, robust portfolio quality, and recent insider buying activity, which have bolstered investor sentiment during broader market volatility.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is currently trending due to intense market speculation surrounding potential high-stakes M&A activity, with the company aggressively positioning its $100 billion investment strategy to bolster its obesity and oncology pipelines. While the stock has faced recent price volatility, the community is actively debating the likelihood of a major acquisition to compete with industry giants, alongside ongoing discussions about the company's long-term growth and its strategic focus on immunology.

Maul Coin

Maul Coin is gaining momentum as community members actively rally to build a long-term foundation, emphasizing transparency and active creator involvement to distinguish the project from typical pump-and-dump schemes. The community is focused on increasing holder count, driving social media engagement, and pushing for official chart verification to fuel organic growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The agency’s assessment was based on the company’s Phase 2 data package.</li><li>The FDA supported the use of Clinical Dementia Rating Scale-Sum of Boxes, a scale used to determine dementia severity.</li><li>INmune will enroll about 300 participants over nine months to confirm efficacy before expanding to a 1,000-patient Phase 3 trial.</li></ul>INmune Bio, Inc (INMB) stock gave up some of its pre-market gains to trade 3% higher on Thursday morning, after the company said it has received official U.S. Food and Drug Administration (FDA) meeting minutes confirming regulatory alignment on its integrated Phase 2b/3 development plan for XPro1595, a potential therapy for early Alzheimer’s disease.The FDA supported INmune Bio’s precision medicine strategy, which uses a trial design to identify patients whose inflammatory biomarker profiles are tied to soluble tumor necrosis factor (TNF) signalling, the treatment’s biological target.The agency’s assessment was based on the company’s Phase 2 data package, which included cognitive and biomarker findings.“XPro1595 represents a differentiated approach to Alzheimer’s disease, based on precision patient selection and selective immune modulation, with a favorable safety profile that included zero cases of ARIA in our Phase 2 study,” said David Moss, INmune Bio’s CEO.<h2 class="st-heading-2">FDA Approval Details</h2>The FDA supported the use of the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) as the primary endpoint, a scale used to assess dementia severity and track progression. It also did not object to INmune Bio’s plan to enroll patients identified by key inflammation-related biomarkers linked to the drug’s target.The company said that the Phase 2b part will feature a nine-month evaluation period to build the clinical foundation for a subsequent Phase 3 study. INmune will enroll about 300 participants over nine months to confirm efficacy before expanding to a 1,000-patient Phase 3 trial lasting 18 months.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned’ bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/INMB_jpg_241e60ecf9.webp" alt="INMB.jpg">One user noted a tepid market reaction and said that it was an “excellent time to add” the stock to their portfolio.<stembedurl>https://stocktwits.com/10baggerPete/message/644778292</stembedurl>Another user said the company was “moving in the right direction.”<stembedurl>https://stocktwits.com/bioinvestorrr/message/644769951</stembedurl><a href="https://stocktwits.com/symbol/INMB">INMB shares</a> have declined around 0.6% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-retail-sales-slump-in-january/cZRTn3fR4rK">Tesla’s China Retail Sales Slump 45% In January: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial?

The FDA meeting minutes suggest INmune Bio’s late-stage Alzheimer’s trial design is on track.

Equity

INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised INmune Bio from a "sell" rating to a "hold" rating in a research note on Sunday...

Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB

Praetorian PR LLC lowered its stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 99.3% in the second quarter, according to the company in its most recent disclosure with the Securities and...

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Investing.com --  INmune Bio  (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its investment case.

INmune Bio Inc. (INMB) on Monday said that its experimental drug XPro did not show any effects in the intent-to-treat population in a mid-stage study evaluating its effectiveness in early Alzheimer’s Disease (AD) with biomarkers of inflammation.INmune’s stock fell about 59% in morning trade at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107380/0/en/INmune-Bio-Reports-Key-Findings-from-Phase-2-MINDFuL-Trial-of-XPro-in-Early-Alzheimer-s-Disease.html">trial </a>enrolled 208 participants with early-stage Alzheimer’s to asses the drug’s potential in slowing cognitive decline by tackling neuroinflammation.The primary endpoint of the study was a change in cognition over 6 months on the Early Mild Alzheimer’s Cognitive Composite (EMACC). EMACC is a tool used in clinical trials and research to assess cognitive changes in individuals with early or mild Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI).The primary endpoint was not met in the intent-to-treat population.However, changes in clinical measures of cognition, behavior, and an AD-related biomarker demonstrated a benefit in a subpopulation of 100 early Alzheimer's patients with inflammation biomarkers who were treated with XPro, compared to patients treated with placebo, the company said.CEO RJ Tesi said that the findings lay the foundation for advancing XPro as a “promising treatment option” for Alzheimer’s.XPro treatment was safe and well-tolerated, the company added.<a href="https://stocktwits.com/symbol/INMB">INmune</a> now intends to schedule an end-of-mid-stage meeting with the U.S. Food and Drug Administration (FDA) in the last quarter of 2025 to define the path forward for a pivotal trial to support XPro approval in early Alzheimer’s.Despite the drop in INMune stock during Monday’s trading session, retail sentiment around the stock is trending in the ‘extremely bullish’ territory on Stocktwits.INMB stock is down by about 53% this year and by about 74% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-flu-vaccine-show-positive-results-in-late-stage-trial/chmZitPRR72">Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial

The primary endpoint of the study was not met in the intent-to-treat population, the company said. 

INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results

Investing.com --  INmune Bio  Inc. (NASDAQ:INMB) stock fell 60% in pre-market trading Monday after the company reported mixed results from its Phase 2 MINDFuL trial of XPro in early Alzheimer’s disease patients.

INmune Bio Inc. (INMB) on Friday said that it entered into securities purchase agreements with two healthcare-focused institutional investors for the purchase and sale of 3 million shares of its common stock.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/27/3106725/0/en/INmune-Bio-Inc-Announces-Approximately-19-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html">said</a> that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share. The proceeds from the offering are expected to be about $19 million, excluding costs such as fees to the placement agency Alliance Global Partners.<a href="https://stocktwits.com/symbol/INMB">INmune Bio</a> said that it intends to use the proceeds from the offering for working capital purposes and general corporate purposes.The closing of the offering is expected to occur on or about June 20.INMB shares are down 19% on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around INmune Bio is unmoved within the ‘extremely bullish’ territory over the past 24 hours, while retail chatter stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_2_24_21_PM_png_cb3ab03d42.webp" alt="INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the company is headed to a year-long downtrend.<stembedurl>https://stocktwits.com/CharlesIV/message/619287462</stembedurl>Another user opined that a stock offering before data results is “sketchy.”<stembedurl>https://stocktwits.com/EddieGon/message/619286742</stembedurl>INmune Bio is slated to present topline results from its mid-stage Alzheimer’s trial, the MINDFuL study, on Monday. The trial is testing its lead drug candidate XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation.The MINDFuL study will compare XProTM to placebo to find out whether XPro affects memory, functioning, and behavior. The study will also evaluate whether XPro is safe and tolerable.INMB stock is up by 9% this year and down by about 41% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-stock-rises-on-us-supreme-court-ruling-in-favor-of-health-insurers-covering-preventive-care/chmWPN2RRe5">Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Stock Slumps On 3M Share Offering Ahead Of Mid-stage Trial Data, But Retail Remains Bullish 

The company said that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share.

INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday.The company will present findings from its MINDFuL study, a placebo-controlled trial testing its lead drug candidate XPro in patients showing early signs of Alzheimer’s.&nbsp;The study participants consisted of 208 patients diagnosed with mild cognitive impairment or mild Alzheimer's disease.&nbsp;The average age of the participants was 72 years. In all of the participants, biomarkers of inflammation were present.&nbsp;The inflammatory biomarkers observed were elevated C-reactive protein levels, along with increased ESR and higher HbA1c values and genetic markers such as the APOE ε4 allele.&nbsp;Participants were randomized 2-to-1 to receive weekly doses of XPro or a placebo for just under six months.The main goal of the study is to assess cognitive change using a custom measurement tool called the early and mild Alzheimer's cognitive composite&nbsp;(EMACC), designed to detect subtle shifts in early-stage Alzheimer’s.&nbsp;Previous data showed the EMACC aligns well with other standard assessments like MMSE and CDR-SB.The company reported that over two-thirds of participants carried the APOE ε4 gene, and nearly two-thirds qualified through more than one biomarker.&nbsp;Roughly 72% of patients screened for the trial were not enrolled, mostly due to more advanced disease.In addition to cognitive scoring, the study includes secondary measures such as evaluations of daily living, neuropsychiatric symptoms, and biological markers.XPro is part of the company’s broader immune-targeting drug platform, which focuses on conditions believed to stem from chronic inflammation.&nbsp;<a href="https://stocktwits.com/symbol/INMB">INmune</a> is also exploring XPro for use in depression, alongside other programs for cancer and rare skin disorders.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 344% surge in 24-hour message volume.One user said that the timing of the announcement indicated confidence from the company, noting that results slated for early Monday were unlikely to disappoint.<stembedurl>https://stocktwits.com/winefan/message/619189685</stembedurl>They also referenced commentary from&nbsp;“pharma bro”&nbsp;Martin&nbsp;Shkreli, who previously stated that if the drug proves effective, the stock could surge dramatically, possibly even reaching triple-digit levels.Another user noted the pre-market Monday scheduling as a potentially encouraging signal but said they wouldn’t celebrate until the actual data is released.<stembedurl>https://stocktwits.com/BoilerKing/message/619167991</stembedurl>The stock has risen 27.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week

INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders.

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

INmune Bio Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$1.21
Prev Close	$1.23
Open	$1.20
Dividend Yield	0.00%
50-Day Moving Average	$1.38
Beta	1.56
Avg. Volume	533,712.61
PE Ratio	-0.63

52-Week High	$11.64
52-Week Low	$1.09
Market Capitalization	$32.7M
EPS (Annual)	-$1.86
Price to Book	1.37
Revenue Per Employee	$2,380.95

INMB
INmune Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INMB News

INMBINmune Bio Inc